Johnson & Johnson (NYSE:JNJ) Trading 1.1% Higher

Johnson & Johnson (NYSE:JNJ)’s share price shot up 1.1% during mid-day trading on Wednesday . The stock traded as high as $154.06 and last traded at $153.97. 1,087,994 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 7,280,173 shares. The stock had previously closed at $152.35.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Morgan Stanley raised their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 18th. TD Securities lowered their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Trading Up 0.6 %

The business has a fifty day moving average price of $148.62 and a 200 day moving average price of $153.25. The company has a market capitalization of $386.61 billion, a price-to-earnings ratio of 10.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the firm earned $2.80 EPS. The business’s revenue was up 4.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of JNJ. 4J Wealth Management LLC boosted its stake in Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock valued at $444,000 after buying an additional 62 shares in the last quarter. My Personal CFO LLC boosted its stake in shares of Johnson & Johnson by 1.4% in the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after purchasing an additional 62 shares in the last quarter. Eagle Strategies LLC grew its holdings in shares of Johnson & Johnson by 1.8% during the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock valued at $563,000 after purchasing an additional 63 shares during the last quarter. Brookmont Capital Management increased its position in Johnson & Johnson by 0.4% during the 4th quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares in the last quarter. Finally, Alliance Wealth Advisors LLC UT lifted its stake in Johnson & Johnson by 1.4% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after purchasing an additional 64 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.